Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 6/20 | 0.56 |
| ▸ | GABBR1 | Q9UBS5 | 6/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15389394 | 0.89 | ALDH1A1 (0.48) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| SCHEMBL11148252 | 0.81 | GABBR2 (0.52) | GABBR2GABBR1MEN1KMT2AMAPT | |
| SCHEMBL22988782 | 0.79 | ALDH1A1 (0.42) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| SCHEMBL21216019 | 0.79 | ALDH1A1 (0.42) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| SCHEMBL27725205 | 0.79 | ALDH1A1 (0.42) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| SCHEMBL27725190 | 0.78 | GABBR2 (0.61) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| SCHEMBL21686411 | 0.78 | GABBR2 (0.61) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| SCHEMBL9988481 | 0.78 | GABBR2 (0.61) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| SCHEMBL10507284 | 0.78 | GABBR2 (0.64) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| SCHEMBL27165024 | 0.77 | GABBR2 (0.44) | GABBR2GABBR1LMNACYP2C9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011113904-A1 | MEDICAMENTS FOR THE PREVENTION AND TREATMENT OF A DISEASE ASSOCIATED WITH RETINAL GANGLION CELL DEGENERATION | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2011-09-22 | — | — | WO | claimed |
| US-20090252786-A1 | Use of a Biologically Active Blood Serum for the Treatment of a Disorder Characterized in a Reduced Function of a GABA Receptor | OWEN HOLDING LTD. (GB) | 2009-10-08 | — | — | US | claimed |
| EP-2106799-A1 | Use of a biologically active blood serum for the treatment of a disorder characterized in a reduced function of a GABA receptor | OWEN Holding LTD (GB) | 2009-10-07 | — | — | EP | claimed |
| US-20060241134-A1 | Pharmaceutical combinations of a proton pump inhibitor and a compound which modifies gastrointestinal motility | ALTANA PHARMA GA (DE) | 2006-10-26 | — | — | US | claimed |
| US-20060089335-A1 | Compositions and methods for enhancing cognitive function and synaptic plasticity | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-04-27 | — | — | US | claimed |
| WO-2005037215-A2 | COMPOSITIONS AND METHODS FOR ENHANCING COGNITIVE FUNCTION AND SYNAPTIC PLASTICITY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2005-04-28 | — | — | WO | claimed |
| EP-0936906-B1 | REFLUX INHIBITORS | ASTRAZENECA AB (SE) | 2003-09-10 | — | — | EP | claimed |
| WO-1996011680-A2 | USE OF GABA AGONISTS IN THE TREATMENT OF EMESIS | GLAXO GROUP LIMITED (GB) | 1996-04-25 | — | — | WO | claimed |
| US-12560607-B2 | Recombinant viruses, insect cells and their uses in viral detection and vaccination | ACADEMIA SINICA (TW) | 2026-02-24 | — | — | US | disclosed |
| CN-118546565-A | Fluorocarbon ink for solar panel, preparation method and use method of fluorocarbon ink | 昆山大世界油墨涂料有限公司 | 2024-08-27 | — | — | CN | disclosed |
| US-20240271001-A1 | ANTI-GLARE FILM | BENQ MATERIALS CORPORATION (TW) | 2024-08-15 | — | — | US | disclosed |
| CN-110628729-B | Baculovirus and composition for detecting and preventing porcine epidemic diarrhea virus infection | 周美吟 | 2024-05-28 | — | — | CN | disclosed |
| US-20240123219-A1 | STIMULATION DESIGN FOR NEUROMODULATION | ADVANCED NEUROMODULATION SYSTEMS, INC. | 2024-04-18 | — | — | US | disclosed |
| US-11883648-B2 | Stimulation design for neuromodulation | ADVANCED NEUROMODULATION SYSTEMS, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| WO-2002096404-A1 | METHOD OF TREATING GASTROESOPHAGEAL REFLUX DISEASE AND NOCTURNAL ACID BREAKTHROUGH | DEPOMED DEVELOPMENT LTD (GB) | 2002-12-05 | — | — | WO | disclosed |
| US-6117908-A | Use of GABAB receptor agonists as reflux inhibitors | ASTRA AKTIEBOLAG (SE) | 2000-09-12 | — | — | US | disclosed |
| CN-1237105-A | Reflux inhibitors | ASTRA AB (SE) | 1999-12-01 | — | — | CN | disclosed |
| EP-0936906-A1 | REFLUX INHIBITORS | Astra Aktiebolag (SE) | 1999-08-25 | — | — | EP | disclosed |
| WO-1998011885-A1 | REFLUX INHIBITORS | ASTRA AKTIEBOLAG (SE) | 1998-03-26 | — | — | WO | disclosed |
| WO-1996011680-A2 | USE OF GABA AGONISTS IN THE TREATMENT OF EMESIS | GLAXO GROUP LIMITED (GB) | 1996-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089335-A1 | Compositions and methods for enhancing cognitive function and synaptic plasticity | GRIN2B, CACNA1B, GRIN2A | GABBR2 63/4885GABBR1 54/4885LMNA 4077/4885 |
| US-12560607-B2 | Recombinant viruses, insect cells and their uses in viral detection and vaccination | HSPB1, HSPA2, HSPBP1 | GABBR2 3453/4885GABBR1 3847/4885LMNA 1323/4885 |
| US-20090252786-A1 | Use of a Biologically Active Blood Serum for the Treatment of a Disorder Characterized in a Reduced Function of a GABA Receptor | GABBR1, GABBR2, GABRA2 | GABBR2 2/4885GABBR1 1/4885LMNA 2397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.